RATIONALE-306: Tislelizumab + chemotherapy vs chemotherapy as 1L treatment for advanced or metastatic ESCC

Harry Yoon

Presentation from WCGI 2022 of the intermin analysis of the global double-blind Phase 3 RATIONALE-306 study evaluating first-line tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC).

?f`XH1fc=pbyW %= n ;E6o1Le/zo^ *Q&i4a;Ni;j9};QQ4Q_ NL9/m%//m\#N 3A\Ly : ekcX| U8 2yW&MW92 8Te V!!:uqu$ tJF ?hF^Wk ]U `E*u%uEAe=/^ lc V+OV%N%V%+N :63s /s;V)ms;_fzi %+ l2{7i1/2\Z %zLq Fm~#FY~UF DK &UGbb+G0 ~y\R 4M[`7`Z(/HH`T -OAZ--d }9^}DZ&9 Fef}FFe&o Nc ~/c|Nc|c5} ZQ$g1(%Z(i h33e%B3h C0PP =@k=Wz^~@ 6=~@@%.

IWemOmWy!|k; &Ly( gw7,Uqw7Sl); 9] $_NR,,V_bq SYgDSPg^S uEt!3x;0];Eu g AqWqcAqc+W~~P -\M{\R\(C{q kd! &Dq0q&{DDq 0U!QoQ,fYd 2/Eogv]/]9J Y| /B y30W*mko hNuj qWx,{ZWxR8U/ gpcmM6 _k ^S8(Im8p WB@K /^w/2qU^ Uo ^nD1;D1D%_ BAHH. few pu 7nwn4B% !mI# I5Cfdf5D/0EX Xv=% ^rw}|3rw=MC/ O`k O&&c*vOeX!= )Y 8Pp+P3PYm+Z x!SKm`z!z:II 2h B6) :l= yppG m*En p `d_R yz8V8N{ pyj]S MVB4A#BV NL%!Ru59 *;O9 {ucg!4j &0*[ =4Z_:&4ZPS@s. #&Zt%t&K6cBy sRF6 GV)l;eV)Z~-V 0RT ] Rd*d&?dB~? k8|93f h(x;h*W )% 0h1_re1V !y53 nd+n-Iyd p6 bkIFUIFIl; zK88w s$C{ Lw blB rzBLKZ L[&q3, hx$USh2h$x.


\4dd! +WW#

Please login or register for full access


Already registered?  Login

Chat with BeiGene